Drug Trial Radar · NCT02302807
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Last checked: Nov 19, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
931
Actual
Start
Jan 13, 2015
Primary completion
Mar 13, 2017
Study completion Nov 8, 2018
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
Conditions
- Bladder Cancer
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibodyDrug
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
DocetaxelDrug
Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
PaclitaxelDrug
Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
VinflunineDrug
Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled
Locations
217 sites in 29 countries. Site status is shown where the registry gives one.
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia
Emory University; Winship Cancer Institute
Atlanta, Georgia
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Duke Cancer Center
Durham, North Carolina
Bon Secours - St. Francis Hospital
Greenville, South Carolina
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee
Royal Brisbane and Women's Hospital; Medical Oncology
Herston, Queensland, Australia
Royal Adelaide Hospital; Oncology
Adelaide, South Australia, Australia
Monash Medical Centre; Oncology
Clayton, Victoria, Australia
Austin and Repatriation Medical Centre; Cancer Services
Melbourne, Victoria, Australia
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
Vienna, Austria
Kaiser-Franz-Josef-Spital; Zent.Onkologie und Hamatologie
Vienna, Austria
ZNA Middelheim
Antwerp, Belgium
Institut Jules Bordet
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Tom Baker Cancer Centre-Calgary
Calgary, Alberta, Canada
Bcca - Cancer Center Southern Interior
Kelowna, British Columbia, Canada
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Bcca - Vancouver Island Cancer Centre; Oncology
Victoria, British Columbia, Canada
Royal Victoria Hospital
Barrie, Ontario, Canada
London Regional Cancer Centre
London, Ontario, Canada
Lakeridge Health Oshawa; Oncology
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre; Oncology
Ottawa, Ontario, Canada
Sault Area Hospitals
Sault Ste. Marie, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
Montreal, Quebec, Canada
Masarykuv onkologicky ustav
Brno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
MULTISCAN, s.r.o., Radiologicke centrum Pardubice
Pardubice, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Herlev Hospital; Onkologisk afdeling
Herlev, Denmark
Rigshospitalet; Onkologisk Klinik
København Ø, Denmark
Docrates Cance Center
Helsinki, Finland
Turku University Central Hospital; Urology clinic
Turku, Finland
Ico - Paul Papin
Angers, France
Institut Sainte Catherine;Recherche Clinique
Avignon, France
Chr De Besancon - Hopital Jean Minjoz
Besançon, France
Hopital Saint Andre
Bordeaux, France
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.